Oxford Biodynamics PLC (OBD) - Net Assets
Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has net assets worth GBX1.12 Million GBX (≈ $135.78 USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX8.09 Million ≈ $983.83 USD) and total liabilities (GBX6.97 Million ≈ $848.05 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Oxford Biodynamics PLC to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.12 Million |
| % of Total Assets | 13.8% |
| Annual Growth Rate | -7.75% |
| 5-Year Change | -83.33% |
| 10-Year Change | -85.59% |
| Growth Volatility | 63.87 |
Oxford Biodynamics PLC - Net Assets Trend (2013–2025)
This chart illustrates how Oxford Biodynamics PLC's net assets have evolved over time, based on quarterly financial data. Also explore OBD asset base for the complete picture of this company's asset base.
Annual Net Assets for Oxford Biodynamics PLC (2013–2025)
The table below shows the annual net assets of Oxford Biodynamics PLC from 2013 to 2025. For live valuation and market cap data, see OBD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | GBX1.12 Million ≈ $135.78 |
-74.39% |
| 2024-09-30 | GBX4.36 Million ≈ $530.24 |
-28.03% |
| 2023-09-30 | GBX6.05 Million ≈ $736.72 |
+133.96% |
| 2022-09-30 | GBX2.59 Million ≈ $314.88 |
-61.33% |
| 2021-09-30 | GBX6.69 Million ≈ $814.34 |
-50.72% |
| 2020-09-30 | GBX13.58 Million ≈ $1.65K |
-22.81% |
| 2019-09-30 | GBX17.59 Million ≈ $2.14K |
-12.24% |
| 2018-09-30 | GBX20.05 Million ≈ $2.44K |
+72.91% |
| 2017-09-30 | GBX11.60 Million ≈ $1.41K |
+49.75% |
| 2016-09-30 | GBX7.74 Million ≈ $942.10 |
-14.37% |
| 2015-09-30 | GBX9.04 Million ≈ $1.10K |
+72.72% |
| 2014-09-30 | GBX5.24 Million ≈ $636.95 |
+78.18% |
| 2013-09-30 | GBX2.94 Million ≈ $357.47 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oxford Biodynamics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4658900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX4.83 Million | 432.89% |
| Other Comprehensive Income | GBX3.08 Million | 275.54% |
| Other Components | GBX45.38 Million | 4066.22% |
| Total Equity | GBX1.12 Million | 100.00% |
Oxford Biodynamics PLC Competitors by Market Cap
The table below lists competitors of Oxford Biodynamics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kiliaro AB
ST:KILI
|
$107.21K |
|
Catalyst Media Group PLC
LSE:CMX
|
$107.83K |
|
Slate Grocery REIT
TO:SGR-U
|
$107.89K |
|
NB Distressed Debt New Glb
LSE:NBDG
|
$107.95K |
|
W.H.Ireland Group
LSE:WHI
|
$105.74K |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
$105.36K |
|
Critical Metals Plc
LSE:CRTM
|
$105.24K |
|
Qlosr Group AB Series B
ST:QLOSR-B
|
$105.22K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oxford Biodynamics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,358,000 to 1,116,000, a change of -3,242,000 (-74.4%).
- Net loss of 11,153,000 reduced equity.
- New share issuances of 7,440,000 increased equity.
- Other comprehensive income decreased equity by 134,000.
- Other factors increased equity by 605,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-11.15 Million | -999.37% |
| Share Issuances | GBX7.44 Million | +666.67% |
| Other Comprehensive Income | GBX-134.00K | -12.01% |
| Other Changes | GBX605.00K | +54.21% |
| Total Change | GBX- | -74.39% |
Book Value vs Market Value Analysis
This analysis compares Oxford Biodynamics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 254.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.89x to 254.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-09-30 | GBX0.23 | GBX0.21 | x |
| 2014-09-30 | GBX0.41 | GBX0.21 | x |
| 2015-09-30 | GBX0.10 | GBX0.21 | x |
| 2016-09-30 | GBX0.09 | GBX0.21 | x |
| 2017-09-30 | GBX0.14 | GBX0.21 | x |
| 2018-09-30 | GBX0.23 | GBX0.21 | x |
| 2019-09-30 | GBX0.19 | GBX0.21 | x |
| 2020-09-30 | GBX0.15 | GBX0.21 | x |
| 2021-09-30 | GBX0.07 | GBX0.21 | x |
| 2022-09-30 | GBX0.03 | GBX0.21 | x |
| 2023-09-30 | GBX0.04 | GBX0.21 | x |
| 2024-09-30 | GBX0.02 | GBX0.21 | x |
| 2025-09-30 | GBX0.00 | GBX0.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oxford Biodynamics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -999.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1018.54%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 7.25x
- Recent ROE (-999.37%) is below the historical average (-152.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -36.12% | -301.43% | 0.10x | 1.23x | GBX-1.35 Million |
| 2014 | -14.10% | -111.68% | 0.11x | 1.18x | GBX-1.26 Million |
| 2015 | -11.13% | -143.16% | 0.07x | 1.08x | GBX-1.91 Million |
| 2016 | -22.40% | -158.57% | 0.12x | 1.17x | GBX-2.50 Million |
| 2017 | -32.86% | -321.56% | 0.09x | 1.10x | GBX-4.96 Million |
| 2018 | -9.75% | -164.67% | 0.06x | 1.05x | GBX-3.96 Million |
| 2019 | -15.93% | -308.71% | 0.05x | 1.07x | GBX-4.56 Million |
| 2020 | -31.80% | -945.83% | 0.03x | 1.13x | GBX-5.67 Million |
| 2021 | -100.09% | -1959.53% | 0.02x | 2.30x | GBX-7.35 Million |
| 2022 | -259.27% | -4357.14% | 0.01x | 4.38x | GBX-6.97 Million |
| 2023 | -178.79% | -2122.75% | 0.03x | 2.66x | GBX-11.43 Million |
| 2024 | -265.42% | -1818.71% | 0.05x | 2.78x | GBX-12.00 Million |
| 2025 | -999.37% | -1018.54% | 0.14x | 7.25x | GBX-11.26 Million |
Industry Comparison
This section compares Oxford Biodynamics PLC's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $412,192,685
- Average return on equity (ROE) among peers: -12.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oxford Biodynamics PLC (OBD) | GBX1.12 Million | -36.12% | 6.25x | $107.03K |
| Abingdon Health Plc (ABDX) | $-115.66K | 0.00% | 0.00x | $259.67K |
| ANGLE plc (AGL) | $40.06 Million | -54.13% | 0.24x | $94.18K |
| genedrive plc (GDR) | $12.05 Million | -9.65% | 0.17x | $119.01K |
| Integrated Diagnostics Holdings PLC (IDHC) | $2.79 Billion | 50.55% | 1.23x | $325.54 Million |
| LungLife AI Inc (LLAI) | $20.13 Million | -36.98% | 0.09x | $15.48K |
| Proteome Sciences PLC (PRM) | $-766.53K | 0.00% | 0.00x | $71.69K |
| Verici Dx Plc (VRCI) | $19.62 Million | -36.19% | 0.03x | $88.39K |
About Oxford Biodynamics PLC
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more